Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InxMed Raises $50 Million for Resistance-Fighting Cancer Therapies

publication date: Mar 4, 2022

Nanjing InxMed raised $50 million in a Series B round to develop innovative therapies that target the stroma microenvironment and drug resistance for hard-to-treat solid tumors. The company's lead drug, IN10018,  is a selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor that is being tested in trials for  metastatic melanoma, platinum-resistant ovarian cancer and triple negative breast cancer. InxMed will use the funds to support clinical trials of IN10018 for multiple cancer types in the US and China, including starting pivotal trials. The Series B was led by CS Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital